Positive phase 3 results reported in trial for new COVID-19 vaccine supported by Cambridge
A clinical trial supported by the NIHR Cambridge BRC and NIHR Cambridge CRF for a new vaccine against COVID-19 has received positive Phase 3 results.
The trial has been taking place at 22 locations across the UK and recruited a total of 4012 participants aged 18 years and over, and 660 adolescents.
Results showed in October 2021, that the vaccine was successful in producing high levels of neutralising antibodies against the COVID-19.
Developed by the French specialty vaccine company Valneva and manufactured in Scotland, the vaccine is the only inactivated, adjuvanted COVID-19 vaccine in clinical development in Europe. This means, that like flu and polio vaccines, it contains dead versions of the virus that cannot cause disease. Valneva hopes to initially get the jab approved for those aged between 18 and 55.
This national trial was supported at the Cambridge site by the NIHR Cambridge Clinical Research Facility and NIHR Cambridge BRC.
